Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Dr. Nathan Mata, the company's Chief Scientific Officer, will present a corporate update on August 15, 2024, at 7:00 am ET.
The presentation will be available as a webcast under the "Events" tab on Belite Bio's investor relations website. Interested parties can access the replay, which will be archived for 90 days following the presentation date. This event provides an opportunity for Belite Bio to showcase its progress in developing novel therapeutics for unmet medical needs in retinal diseases.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases, has announced a webcast scheduled for August 12, 2024, at 4:30 p.m. Eastern Time. The purpose of this webcast is to discuss the company's financial results for the second quarter ended June 30, 2024, and provide a business update.
Investors and interested parties can access the live webcast through the provided link or via the 'Presentations & Events' section of Belite Bio's Investor Relations website. A replay of the webcast will be available for approximately 90 days after the event, allowing those unable to attend the live session to review the information at their convenience.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical firm specializing in treatments for degenerative retinal diseases, announced that its Chief Scientific Officer, Dr. Nathan Mata, will present a corporate update at the JonesHealthcare Seaside Summit. The event will take place in Encinitas, CA, on July 15, 2024, at 1:00 pm PT. The presentation will be available via webcast on the Belite Bio website under the 'Events' tab, with a replay accessible for 90 days post-presentation.
Belite Bio has received the Sakigake (Pioneer Drug) designation from Japan's MHLW for its lead drug, Tinlarebant, aimed at treating Stargardt Disease (STGD1). Tinlarebant, an oral tablet, has shown promise in a 24-month Phase 2 trial by slowing the progression of atrophic lesions in adolescent STGD1 patients. 42% of participants with known ABCA4 mutations didn't develop new lesions, and no change in existing lesions was observed.
The global Phase 3 trial for adolescent STGD1, named 'DRAGON,' has completed enrollment, with interim results expected in Q4 2024. Additionally, the DRAGON II trial has started, and a global Phase 3 trial for Geographic Atrophy (GA) in Dry AMD, termed 'PHOENIX,' is ongoing. Tinlarebant has also received Orphan Drug Designation in Japan for STGD1 treatment.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical firm, announced its participation in the Benchmark’s 4th Annual Healthcare House Call Investor Conference. The event, set for May 21 and 22, 2024, will be held virtually. Belite Bio's executive management will host a fireside chat at 3:00 pm ET on May 21, 2024. The company focuses on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
Belite Bio (NASDAQ: BLTE) announced its Q1 2024 results and provided a corporate update. The company highlighted positive data from its Phase 2 trial of Tinlarebant in STGD1 patients, showing sustained lower atrophic lesion growth. Tinlarebant is also being evaluated in ongoing Phase 3 trials (DRAGON and PHOENIX) for STGD1 and GA, respectively. Interim data from these trials are expected in Q4 2024. Financially, Belite raised $25 million through a direct offering and reported a net loss of $7.9 million for Q1 2024, up from $6.9 million in Q1 2023. The company held $95.5 million in cash and U.S. treasury bills as of March 31, 2024.
Belite Bio, Inc. (NASDAQ: BLTE) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on May 20, 2024. The company will host a fireside chat at 3:30 pm ET, accessible via webcast on their investor relations website.
Belite Bio, Inc. (NASDAQ: BLTE) will host a webcast on May 14, 2024, to discuss the first quarter 2024 financial results and provide a business update. The company is a clinical-stage biopharmaceutical drug development company focused on degenerative retinal diseases. The webcast will be held at 4:30 p.m. Eastern Time.
Belite Bio, Inc. (BLTE) will participate in a Key Opinion Leader Webinar to discuss Stargardt Disease and Geographic Atrophy and share insights on Tinlarebant, a novel therapeutic. The webinar, moderated by Cantor Fitzgerald, will feature Dr. Michel Michaelides, a renowned expert. Tinlarebant is a promising treatment with Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
Belite Bio presented additional analysis from a Phase 2 study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting. The 24-month trial showed promising results in slowing lesion growth and stabilizing visual acuity. Genetic profiling revealed that despite severe ABCA4 variants, 42% of treated subjects did not develop atrophic retinal lesions. A novel lesion size quantification method was able to detect atrophic lesions more accurately. The drug is now being evaluated in Phase 3 trials for Stargardt Disease and Geographic Atrophy.